

Stephen T Sonis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/708213/stephen-t-sonis-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

10,477
citations

47
h-index

101
g-index

176
ext. papers

11,815
ext. citations

5.6
avg, IF

6.48
L-index

#	Paper	IF	Citations
164	Oral lichen planus: comparative efficacy and treatment costs-a systematic review.. <i>BMC Oral Health</i> , 2022 , 22, 161	3.7	2
163	Increasing HPV Vaccination Coverage on Preventing Oropharyngeal Cancer: A Cost-Effectiveness Analysis.. <i>Tumour Virus Research</i> , 2021 , 13, 200234		0
162	The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. <i>Ca-A Cancer Journal for Clinicians</i> , 2021 ,	220.7	5
161	Superoxide Dismutase as an Intervention for Radiation Therapy-Associated Toxicities: Review and Profile of Avasopasem Manganese as a Treatment Option for Radiation-Induced Mucositis. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 1021-1029	4.4	4
160	A hypothesis for the pathogenesis of radiation-induced oral mucositis: when biological challenges exceed physiologic protective mechanisms. Implications for pharmacological prevention and treatment. <i>Supportive Care in Cancer</i> , 2021 , 29, 4939-4947	3.9	4
159	Healthcare-associated infections among patients hospitalized for cancers of the lip, oral cavity and pharynx. <i>Infection Prevention in Practice</i> , 2021 , 3, 100115	2.1	0
158	GM-1111 reduces radiation-induced oral mucositis in mice by targeting pattern recognition receptor-mediated inflammatory signaling. <i>PLoS ONE</i> , 2021 , 16, e0249343	3.7	1
157	Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers. <i>Supportive Care in Cancer</i> , 2021 , 29, 6061-6068	3.9	6
156	The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis.. <i>Frontiers in Oral Health</i> , 2021 , 2, 689386	0.8	2
155	Network meta-analysis from a pairwise meta-analysis design: to assess the comparative effectiveness of oral care interventions in preventing ventilator-associated pneumonia in critically ill patients. <i>Clinical Oral Investigations</i> , 2021 , 25, 2439-2447	4.2	1
154	Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. <i>Cancer</i> , 2021 , 127, 1796-1804	6.4	8
153	Treatment for Oral Mucositis-Current Options and an Update of Small Molecules Under Development. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 25	5.4	2
152	Benefits of the Involvement of Dentists in Managing Oral Complications Among Patients With Oral Cavity and Oropharyngeal Cancer: An Analysis of Claims Data. <i>JCO Oncology Practice</i> , 2021 , 17, e1668-e1677	2.3	0
151	Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>Oral Diseases</i> , 2021 ,	3.5	3
150	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. <i>Supportive Care in Cancer</i> , 2020 , 28, 5059-5073	3.9	16
149	An update on pharmacotherapies in active development for the management of cancer regimen-associated oral mucositis. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 541-548	4	10
148	Enhanced oral hygiene interventions as a risk mitigation strategy for the prevention of non-ventilator-associated pneumonia: a systematic review and meta-analysis. <i>British Dental Journal</i> , 2020 , 228, 615-622	1.2	11

147	Could the impact of photobiomodulation on tumor response to radiation be effected by tumor heterogeneity?. <i>Supportive Care in Cancer</i> , 2020 , 28, 423-424	3.9	5
146	Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 106, 320-328	4	12
145	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2020 , 126, 4423-4431	6.4	82
144	Disparities in Oral Cancer Screening Among Dental Professionals: NHANES 2011-2016. <i>American Journal of Preventive Medicine</i> , 2019 , 57, 447-457	6.1	10
143	Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3256-3265	2.2	42
142	Oral Mucositis Due to High-Dose Chemotherapy and/or Head and Neck Radiation Therapy. <i>Journal of the National Cancer Institute Monographs</i> , 2019 , 2019,	4.8	14
141	Phase II investigational oral drugs for the treatment of radio/chemotherapy induced oral mucositis. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 147-154	5.9	17
140	Predicting mucositis risk associated with cytotoxic cancer treatment regimens: rationale, complexity, and challenges. <i>Current Opinion in Supportive and Palliative Care</i> , 2018 , 12, 198-210	2.6	9
139	Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm. <i>Cancer Medicine</i> , 2018 , 7, 240-253	4.8	17
138	Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 427-435	4	41
137	Impact of the insurance type of head and neck cancer patients on their hospitalization utilization patterns. <i>Cancer</i> , 2018 , 124, 760-768	6.4	17
136	Biomarkers Associated with Lymphedema and Fibrosis in Patients with Cancer of the Head and Neck. <i>Lymphatic Research and Biology</i> , 2018 ,	2.3	11
135	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. <i>Oncologist</i> , 2017 , 22, 343-350	5.7	30
134	Safety and tolerability of topical clonazepam solution for management of oral dysesthesia. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017 , 124, 146-151	2	8
133	Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2017 , 15, 24-26	5.3	9
132	Oral Complications of Cancer and Their Treatment 2017 , 1-13		
131	The Chicken or the Egg? Changes in Oral Microbiota as Cause or Consequence of Mucositis During Radiation Therapy. <i>EBioMedicine</i> , 2017 , 18, 7-8	8.8	13
130	Genomic data integration in chronic lymphocytic leukemia. <i>Journal of Gene Medicine</i> , 2017 , 19, e2936	3.5	13

129	Exploring Genetic Attributions Underlying Radiotherapy-Induced Fatigue in Prostate Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2017 , 54, 326-339	4.8	6
128	Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017 , 124, 253-260	2	8
127	[P3091]: EFFECTIVE ANALYSIS OF GENE EXPRESSION FOR THE DISCOVERY OF BIOMARKERS AND THERAPEUTIC TARGETS FOR ALZHEIMER'S DISEASE 2017 , 13, P968-P969		
126	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. <i>Frontiers in Pharmacology</i> , 2017 , 8, 354	5.6	96
125	Design of Biomedical Robots for Phenotype Prediction Problems. <i>Journal of Computational Biology</i> , 2016 , 23, 678-92	1.7	22
124	Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. <i>Current Problems in Cancer</i> , 2016 , 40, 244-257	2.3	10
123	Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. <i>International Journal of Cancer</i> , 2016 , 139, 2635-2645	7.5	72
122	Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. <i>Supportive Care in Cancer</i> , 2016 , 24, 2781-92	3.9	116
121	Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. <i>Oral Oncology</i> , 2016 , 54, 7-14	4.4	70
120	A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. <i>PLoS ONE</i> , 2016 , 11, e0152995	3.7	12
119	Could the PI3K canonical pathway be a common link between chronic inflammatory conditions and oral carcinogenesis?. <i>Journal of Oral Pathology and Medicine</i> , 2016 , 45, 469-74	3.3	6
118	Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. <i>Journal of Biotechnology</i> , 2016 , 239, 115-125	3.7	29
117	Pharmacotherapy for the management of cancer regimen-related oral mucositis. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1801-7	4	39
116	Impact of Microarray Preprocessing Techniques in Unraveling Biological Pathways. <i>Journal of Computational Biology</i> , 2016 , 23, 957-968	1.7	6
115	Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 503-8	4.7	13
114	Oral Medicine referrals at a hospital-based practice in the United States. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015 , 119, 423-9	2	13
113	Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. <i>Supportive Care in Cancer</i> , 2015 , 23, 433-9	3.9	8
112	Current understanding of the relationship between periodontal and systemic diseases. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015 , 36, 150-8	1.1	23

111	Mucositis: pathobiology and management. <i>Current Opinion in Oncology</i> , 2015 , 27, 159-64	4.2	156
110	Genomics, personalized medicine, and supportive cancer care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 9-16	7.1	7
109	Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity. <i>Cancer Treatment Reviews</i> , 2015 , 41, 122-8	14.4	31
108	Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11793-803	5.6	20
107	An Outcomes Study of 40 Years of Graduates of a General Practice Dental Residency. <i>Journal of Dental Education</i> , 2015 , 79, 888-896	1.6	3
106	Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 675-80	3.5	21
105	Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. <i>Oral Oncology</i> , 2014 , 50, 1098-103	4.4	21
104	Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities. <i>Frontiers in Pharmacology</i> , 2014 , 5, 51	5.6	46
103	Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation. <i>Mediators of Inflammation</i> , 2014 , 2014, 518261	4.3	41
102	Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. <i>Cancer</i> , 2014 , 120, 1433-40	6.4	43
101	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2014 , 120, 1453-61	6.4	669
100	Oral Mucositis in Head and Neck Cancer: Risk, Biology, and Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , e236-e240	7.1	15
99	Emerging evidence on the pathobiology of mucositis. <i>Supportive Care in Cancer</i> , 2013 , 21, 2075-83	3.9	91
98	Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. <i>Cancer</i> , 2013 , 119, 4268-76	6.4	80
97	Oral mucositis in head and neck cancer: risk, biology, and management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 ,	7.1	46
96	Predicting risk of chemotherapy-induced side effects in patients with colon cancer with single-nucleotide polymorphism (SNP) Bayesian networks (BNs).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 344-344	2.2	2
95	A clinically translatable mouse model for chemotherapy-related fatigue. <i>Comparative Medicine</i> , 2013 , 63, 491-7	1.6	33
94	Long-term symptom burden and orodental health of oropharyngeal cancer (OPC) survivors following treatment with chemoradiotherapy (CRT) or sequential therapy (ST).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9530-9530	2.2	

93	Randomized double-blind placebo-controlled trial of celecoxib for radiation-induced oral mucositis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9620-9620	2.2	
92	Community-based dental evaluation program for hematopoietic cell transplantation.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 143-143	2.2	
91	A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. <i>Supportive Care in Cancer</i> , 2012 , 20, 1797-804	3.9	16
90	New frontiers in mucositis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 545-51	7.1	14
89	A Comparison and Assessment of Scoring Scales for Mucositis 2012 , 39-46		2
88	SNP-Based Bayesian Networks Define Oral Mucositis Risk in Patients Receiving Stomatotoxic Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 735-735		22
87	The quest for effective treatments of mucositis. <i>The Journal of Supportive Oncology</i> , 2011 , 9, 170-1		6
86	Oral mucositis. <i>Anti-Cancer Drugs</i> , 2011 , 22, 607-12	2.4	123
85	Inflammation and genetic risk indicators for early periodontitis in adults. <i>Journal of Periodontology</i> , 2011 , 82, 588-96	4.6	7
84	Regimen-related gastrointestinal toxicities in cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2010 , 4, 26-30	2.6	40
83	Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. <i>Core Evidence</i> , 2010 , 4, 199-205	4.9	37
82	Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. <i>Cancer</i> , 2010 , 116, 210-5	6.4	110
81	Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. <i>Supportive Care in Cancer</i> , 2010 , 18, 95-103	3.9	35
80	Reduced Infection and Mucositis In Chemotherapy-Treated Animals Following Innate Defense Modulation Using a Novel Drug Candidate.. <i>Blood</i> , 2010 , 116, 3781-3781	2.2	
79	Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. <i>Oral Oncology</i> , 2009 , 45, 164-72	4.4	160
78	Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. <i>Oral Oncology</i> , 2009 , 45, 1015-20	4.4	295
77	Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 239-51	3.5	124
76	Links between regimen-related toxicities in patients being treated for colorectal cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2009 , 3, 50-4	2.6	19

75	Management of oral mucositis in patients who have cancer. <i>Dental Clinics of North America</i> , 2008 , 52, 61-77, viii	3.3	320
74	Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. <i>Clinical Cancer Research</i> , 2008 , 14, 4292-7	12.9	68
73	Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. <i>International Journal of Radiation Biology</i> , 2008 , 84, 401-12	2.9	23
72	Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 33-41	3.5	149
71	Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. <i>Cancer</i> , 2008 , 113, 2704-13	6.4	258
70	Updated clinical practice guidelines for the prevention and treatment of mucositis. <i>Cancer</i> , 2007 , 109, 820-31	6.4	585
69	Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. <i>Supportive Care in Cancer</i> , 2007 , 15, 491-6	3.9	106
68	Mucositis: biology and management. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2007 , 15, 123-9	2	80
67	The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. <i>Cancer Treatment Reviews</i> , 2007 , 33, 448-60	14.4	200
66	Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. <i>The Journal of Supportive Oncology</i> , 2007 , 5, 231-5		24
65	Can oral glutamine prevent mucositis in children undergoing hematopoietic stem-cell transplantation?. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 244-5		3
64	Introduction; Oral Care in Advanced Disease; Supportive Care for the Renal Patient; Handbook of Opioid Bowel Syndrome Oral Care in Advanced Disease. Edited by Andrew Davies and Ilora Finley . New York: Oxford University Press, 2005, 221 pp., \$75.00 Supportive Care for the Renal Patient. Edited by Eugene Chertow, Michael S. Soriano, and Felipe Bravo. New York: Oxford University Press, 2005, 200 pp., \$75.00	2.2	
63	New thoughts on the pathobiology of regimen-related mucosal injury. <i>Supportive Care in Cancer</i> , 2006 , 14, 516-8 <i>J. Bin. Journal of Palliative Medicine</i> , 2006, 9, 814-817	3.9	41
62	Dimensional stability of the alveolar ridge after implantation of a bioabsorbable bone graft substitute: a radiographic and histomorphometric study in rats. <i>Journal of Oral Implantology</i> , 2005 , 31, 68-76	1.2	4
61	Single-Dose Prevention or Short-Term Treatment with Fibroblast Growth Factor-20 (CG53135-05) Reduces the Severity and Duration of Oral Mucositis. <i>Supportive Cancer Therapy</i> , 2005 , 2, 122-7		5
60	Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 383-8	4.7	89
59	Palifermin in Myelotoxic Therapy-Induced Oral Mucositis. <i>Drugs</i> , 2005 , 65, 2147-2149	12.1	1
58	Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 134-5		16

57	Oral Mucositis (OM) and Outcomes of Allogeneic (AL) Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hematologic Malignancies.. <i>Blood</i> , 2005 , 106, 3126-3126	2.2	
56	Oral Mucositis (OM) and Outcomes of Autologous (AU) Hematopoietic Stem Cell Transplantation (HSCT) Following High-Dose Melphalan (MP) Conditioning for Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 1343-1343	2.2	
55	New trends in the management of oral mucositis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005 , 3 Suppl 1, S54-6	7.3	
54	The pathobiology of mucositis. <i>Nature Reviews Cancer</i> , 2004 , 4, 277-84	31.3	791
53	Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. <i>Cancer</i> , 2004 , 100, 1995-2025	6.4	1000
52	Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. <i>Cancer</i> , 2004 , 100, 2026-46	6.4	575
51	Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 328-36	4.7	124
50	Pathobiology of mucositis. <i>Seminars in Oncology Nursing</i> , 2004 , 20, 11-5	3.7	125
49	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. <i>Blood</i> , 2004 , 104, 351-351	2.2	3
48	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. <i>Blood</i> , 2004 , 104, 1227-1227	2.2	
47	Oral mucositis in cancer therapy. <i>The Journal of Supportive Oncology</i> , 2004 , 2, 3-8		81
46	The prevention and treatment of radiotherapy - induced xerostomia. <i>Seminars in Radiation Oncology</i> , 2003 , 13, 302-8	5.5	22
45	How should we measure and report radiotherapy-induced xerostomia?. <i>Seminars in Radiation Oncology</i> , 2003 , 13, 226-34	5.5	109
44	Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. <i>Cancer</i> , 2003 , 98, 406-12	6.4	47
43	Antimicrobial therapy to prevent or treat oral mucositis. <i>Lancet Infectious Diseases, The</i> , 2003 , 3, 405-12	25.5	95
42	A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). <i>Leukemia and Lymphoma</i> , 2003 , 44, 1165-72	1.9	51
41	Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. <i>Clinical Cancer Research</i> , 2003 , 9, 3454-61	12.9	37
40	The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. <i>Critical Reviews in Oral Biology and Medicine</i> , 2002 , 13, 380-9		153

39	Nanoparticulate Hydroxyapatite Enhances the Bioactivity of a Resorbable Bone Graft. <i>Materials Research Society Symposia Proceedings</i> , 2002 , 735, 641		
38	Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. <i>Blood</i> , 2002 , 100, 3479-82	2.2	148
37	Oral complications of cancer therapy. <i>Oncology</i> , 2002 , 16, 680-6; discussion 686, 691-2, 695	1.8	53
36	Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2201-5	2.2	471
35	Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. <i>Cancer</i> , 1999 , 85, 2103-13	6.4	259
34	Risk factors affecting hospital length of stay in patients with odontogenic maxillofacial infections. <i>Journal of Oral and Maxillofacial Surgery</i> , 1996 , 54, 1386-91; discussion 1391-2	1.8	60
33	Section Reviews: Biologicals & Immunologicals: Pharmacological attenuation of chemotherapy-induced oral mucositis. <i>Expert Opinion on Investigational Drugs</i> , 1996 , 5, 1155-1162	5.9	4
32	Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. <i>Transplantation</i> , 1996 , 62, 1278-85	1.8	54
31	A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. <i>Cancer</i> , 1993 , 72, 1612-7	6.4	195
30	Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1993 , 76, 45-8		27
29	Effect of medical status on dental procedure time. <i>Special Care in Dentistry</i> , 1992 , 12, 71-3	1.7	6
28	Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1992 , 74, 749-55		69
27	An animal model for mucositis induced by cancer chemotherapy. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1990 , 69, 437-43		132
26	The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients. <i>Cancer</i> , 1990 , 66, 2375-9	6.4	47
25	In vivo and in vitro effects of beta-carotene and algae extracts in murine tumor models. <i>Nutrition and Cancer</i> , 1989 , 12, 371-80	2.8	6
24	Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1988 , 65, 19-22		54
23	Preservation of the alveolar ridge with hydroxyapatite-collagen implants in rats. <i>Journal of Prosthetic Dentistry</i> , 1988 , 60, 729-34	4	13
22	An analysis of dental services based in the emergency room. <i>Special Care in Dentistry</i> , 1988 , 8, 106-8	1.7	14

21	Manual of oral and maxillofacial surgery. <i>Special Care in Dentistry</i> , 1988 , 8, 40-40	1.7	
20	Hospital dentistry: is there a future?. <i>Special Care in Dentistry</i> , 1987 , 7, 243-243	1.7	
19	Increased efficiency of immunotherapy using irradiated tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 1987 , 24, 68-71	7.4	2
18	Oral complications of multimodality therapy for advanced squamous cell carcinoma of head and neck. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1986 , 61, 139-41		21
17	Significance of the head and neck in late infection in renal transplant recipients. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1986 , 62, 524-8		1
16	Healing of spontaneous periodontal defects in dogs treated with xenogeneic demineralized bone. <i>Journal of Periodontology</i> , 1985 , 56, 470-9	4.6	12
15	Interaction of Ia antigen-bearing polymorphonuclear leukocytes and murine splenocytes. <i>Inflammation</i> , 1983 , 7, 25-33	5.1	7
14	Severe oral hemorrhage and sepsis following bone marrow transplant failure. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1983 , 56, 483-6		4
13	The antigenicity of electrocauterized allogeneic tumor cells in mice. <i>Journal of Surgical Research</i> , 1982 , 33, 17-22	2.5	2
12	Effects of supernatants of polymorphonuclear neutrophils recruited by different inflammatory substances on mitogen responses of lymphocytes. <i>Inflammation</i> , 1982 , 6, 1-11	5.1	16
11	Alterations in the oral mucosa caused by chemotherapeutic agents. A histologic study. <i>The Journal of Dermatologic Surgery and Oncology</i> , 1981 , 7, 1019-25		103
10	Utilization of inpatient dental consultation services. <i>Special Care in Dentistry</i> , 1981 , 1, 18-21	1.7	10
9	The presence of lymphoblasts in the gingival crevice of children with acute lymphoblastic leukemia. <i>Journal of Periodontology</i> , 1981 , 52, 276-9	4.6	4
8	Modification of in vitro and in vivo immune function by acute inflammatory cells. <i>Transplantation</i> , 1980 , 30, 244-50	1.8	10
7	Oral pathoses as diagnostic indicators in leukemia. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1980 , 50, 134-9		55
6	Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1979 , 48, 21-8		85
5	Chlorhexidine-induced lingual keratosis and dysplasia in rats. <i>Journal of Periodontology</i> , 1978 , 49, 585-91	4.6	18
4	The role of effector cells and antiserum in the inhibition of cell-mediated cytotoxicity of allogeneic tumor cells. <i>Transplantation</i> , 1976 , 22, 52-60	1.8	2

3	The incidence of mast cells in selected oral lesions. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1972 , 34, 245-8		7
2	In vitro effects of isobutyl cyanocrylate on four types of bacteria. <i>Journal of Dental Research</i> , 1971 , 50, 1557-8	8.1	31
1	Oral Mucosal Complications of Cancer Therapy87-99		1